Efinopegdutide: Research Profile is part of the Novusyn Research editorial desk. Efinopegdutide (MK-6024) clinical profile: dual glucagon/GLP-1 agonist, Phase 2b liver-fat reduction in MASH, weekly dosing, and Merck pipeline status. This prerendered HTML exists so crawlers see route-specific content before the client app hydrates.
For adjacent coverage, see the news desk, clinical trials tracker, regulation tracker, guides library, and the compound directory. Novusyn Research publishes neutral, research-only reference material and does not sell compounds or provide medical advice.